Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3537982 in Chinese Patients With KRAS G12C-Mutant Advanced Solid Tumors
NCT06235983Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olomorasib in solid tumor, sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Plasma Concentration at 18 weeks and Area Under the Plasma Concentration Versus Time Curve at 18 weeks. Started Feb 2024; status: completed.
02
Drugs
olomorasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06235983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235983.